Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -44.26% is 55% above its 4-year average of -99.10%, near the high end of its 4-year range (-834.69%–-28.52%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.26% above its 12-month average of -48.25%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -44.26%.
RETURN ON EQUITY (ROE)
-44.26%
RETURN ON EQUITY (ROE) AVG TTM
-48.25%
RETURN ON EQUITY (ROE) AVG 3Y
-43.58%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+8.26%
CURRENT VS 3Y AVG
-1.57%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.46%
median of 339 covered companies
CURRENT VS SECTOR MEDIAN
-55.52%
vs the sector median at left
Alpha Cognition Inc
Market Cap
$142.11M
Return on Equity (ROE)
-44.26%
TTM Avg
-48.25%
3Y Avg
-43.58%
5Y Avg
N/A
Market Cap
$142.49M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
Market Cap
$134.74M
Return on Equity (ROE)
-11.20%
TTM Avg
-11.86%
3Y Avg
-12.45%
5Y Avg
-5.17%
Market Cap
$149.51M
Return on Equity (ROE)
-93.22%
TTM Avg
-92.28%
3Y Avg
-73.94%
5Y Avg
-53.80%
Market Cap
$152.16M
Return on Equity (ROE)
-155.34%
TTM Avg
-168.75%
3Y Avg
-117.97%
5Y Avg
-104.46%
Market Cap
$152.45M
Return on Equity (ROE)
-21.38%
TTM Avg
-42.33%
3Y Avg
-37.95%
5Y Avg
-45.57%
Market Cap
$153.84M
Return on Equity (ROE)
-183.44%
TTM Avg
-114.28%
3Y Avg
-67.72%
5Y Avg
-46.03%
Market Cap
$129.14M
Return on Equity (ROE)
-234.42%
TTM Avg
-102.69%
3Y Avg
-100.55%
5Y Avg
-100.92%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Cognition Inc (ACOG) | $142.11M | -44.26% | -48.25% | -43.58% | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | 68.12% | -94.32% | -166.28% | -128.51% |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $134.74M | -11.20% | -11.86% | -12.45% | -5.17% |
| Codexis, Inc. (CDXS)vs › | $149.51M | -93.22% | -92.28% | -73.94% | -53.80% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | -155.34% | -168.75% | -117.97% | -104.46% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -21.38% | -42.33% | -37.95% | -45.57% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | -183.44% | -114.28% | -67.72% | -46.03% |
| Entera Bio Ltd. (ENTX)vs › | $129.14M | -234.42% | -102.69% | -100.55% | -100.92% |
| Cibus, Inc. (CBUS)vs › | $128.24M | -663.38% | -427.48% | -294.92% | -251.31% |
ROE
-44.3%
ROA
-36.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -44.26% |
| 2026-03-31 | -43.76% |
| 2025-12-31 | -33.06% |
| 2025-09-30 | -57.42% |
| 2025-06-30 | -62.75% |
| 2025-03-31 | -28.52% |
| 2024-12-31 | -35.29% |
| 2023-03-31 | -834.69% |
| 2022-09-30 | -633.70% |
| 2022-06-30 | -321.20% |
| 2022-03-31 | -149.76% |
| 2021-12-31 | -215.00% |
